Skip to content
Current New
Menu
  • BUSINESS
  • ARTICLES
  • FEATURES
  • SENIOR LEADERSHIP
  • BusinessWireIndia
Menu

Jagat Pharma & Dr Basu Group Endeavours for 250+ Crore Revenue by Fiscal Year 2027

Posted on December 16, 2024

 

Jagat Pharma, a trusted name in Ayurvedic wellness, is poised for remarkable growth as it targets revenue exceeding ₹250 crore by the financial year 2027. Renowned for its expertise in Ayurvedic eye care and wellness products, the company has steadily expanded its reach across India and beyond, combining a legacy of over 42 years with innovative strategies.

 

The company has an impressive reach in the offline space also, with over 200 distributors across 17+ states. This includes a strong presence in South India with 50+ distributors for a territory that is embracing Ayurvedic solutions in increasing folds. With yearly 200% growth its online space dominance gives it a 60% market share in the Ayurvedic eye care segment as well. The company makes its products available to millions of customers across the country by using this comprehensive dual-channel strategy.

 

Jagat Pharma’s ambitious expansion plans extend far beyond Indian borders. The company is actively preparing to enter the lucrative markets of the Middle East and African countries, tapping into regions with a rising demand for holistic healthcare solutions. A significant milestone in its international journey is its imminent entry into the United States, with exports slated to begin in December 2024. This step is backed by Jagat Pharma’s commitment to quality and compliance, as evidenced by its recent USFDA certification. Combined with its existing WHO-GMP certification, the company is well-positioned to meet the stringent global standards required to compete in international markets.

 

Domestically, Dr. Basu Group is increasing infrastructure growth by expanding its presence in metropolitan cities, including Mumbai, Noida Gurugram. It is a prudent move by the company to bring Ayurvedic

 

 

solutions closer to the minds of people who are seeking natural alternatives for health and wellness in urban settings. In alignment with market needs, the infrastructure growth of Jagat Pharma aims to further solidify its leadership in the Ayurvedic wellness space.

 

Company’s Director Dr Mandeep Singh Basu says “At Jagat Pharma, we are driven by a vision to make holistic Ayurvedic solutions accessible to people worldwide. Our move to expand into the global market, diversification into nutraceuticals, and focus on innovation reflect a continuous focus on health and wellness enhancement. We don't merely set revenue targets but redefine the future of natural healthcare. Together, we aim to touch lives and make a meaningful impact globally.”

 

 

Recognizing the growing demand for holistic health products, Jagat Pharma is diversifying its product portfolio to cater to a broader audience as it plans to enter the nutraceutical and dietary supplement sector. Its dedication to blending Ayurvedic principles with modern science fosters the company's consistent growth. Entering this growth stride, the company is committed to bringing holistic health solutions to every nook and corner of the world. By taking advantage of its strong distribution network, Jagat Pharma reaches new markets and innovates through the wellness industry to not only achieve its revenue target but redefine the future of Ayurvedic healthcare on a global scale.

 

LATEST NEWS

  • Micro Finance Industry Network (MFIN)’s 57th edition of Micrometer for Q4 FY 25-26 based on the industry position as on March 31, 2026
  • Cosmo First Advances Piyush Gupta to Lead Cosmo Speciality Chemicals as Business Head
  • APM Terminals Pipavav Ranked India’s Second-Best Performing Container Port and 28th Globally in CPPI 2025
  • Greenply Launches a First-of-Its-Kind Green Commitment, ‘Naam Se Hi Nahi, Kaam Se Bhi Green’
  • Sharath Chandra Maroju receives FTCCI Excellence Award 2026 for Science and Engineering

Past News

  • June 2026 (29)
  • May 2026 (57)
  • April 2026 (89)
  • March 2026 (83)
  • February 2026 (67)
  • January 2026 (74)
  • December 2025 (57)
  • November 2025 (49)
  • October 2025 (102)
  • September 2025 (97)
  • August 2025 (86)
  • July 2025 (91)
  • June 2025 (87)
  • May 2025 (90)
  • April 2025 (80)
  • March 2025 (80)
  • February 2025 (61)
  • January 2025 (56)
  • December 2024 (46)
  • November 2024 (48)
  • October 2024 (66)
  • September 2024 (53)
  • August 2024 (42)
  • July 2024 (35)
  • June 2024 (33)
  • May 2024 (35)
  • April 2024 (43)
  • March 2024 (41)
  • February 2024 (30)
  • January 2024 (41)
©2026 Current New | Design: Newspaperly WordPress Theme